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ABSTRACT
Although levodopa is widely recognized as the most effective therapy for Parkinson disease (PD),
its introduction 5 decades ago was preceded by several years of uncertainty and equivocal clin-
ical results. The translation of basic neuroscience research by Arvid Carlsson and Oleh Hornykie-
wicz provided a logical pathway for treating PD with levodopa. Yet the pioneering clinicians who
transformed PD therapeutics with this drug—among them Walther Birkmayer, Isamu Sano, Pat-
rick McGeer, George Cotzias, Melvin Yahr, and others—faced many challenges in determining
whether the concept and the method for replenishing deficient striatal dopamine was correct.
This article reviews highlights in the early development of levodopa therapy. In addition, it pro-
vides an overview of emerging drug delivery strategies that show promise for improving levodo-
pa’s pharmacologic limitations. Neurology® 2016;86 (Suppl 1):S3–S12
GLOSSARY
CNS 5 central nervous system; PD 5 Parkinson disease; TOPA 5 2,4,5-trihydroxyphenylalanine.
Among neurodegenerative diseases, Parkinson disease (PD) is unique in having several highly
effective medications for suppressing its signs and symptoms. Heading the list of treatment op-
tions over the past 5 decades has been a remarkably effective medication: levodopa (3,4-
dihydroxy-L-phenylalanine; also known as L-DOPA).1–3 Its worldwide impact on reversing
the disabilities of PD and improving quality of life has been enormous, though it arrived on
the therapeutics scene amidst skepticism and, initially, unfulfilled promise.4,5 Eventually, after
almost a decade of unconvincing clinical trials, levodopa finally proved itself to be a successful
therapy.6,7 It provided the first opportunity for clinician and patient alike to recognize how
much of the parkinsonian motor syndrome—resting tremor, slowed movement, decreased
dexterity, rigidity, postural disturbance, and other impairments—are reversible consequences
of striatal dopaminergic deficiency. Levodopa has also been one of the most cost-effective
medications ever developed. Although, after nearly a half-century of use, this medication con-
tinues to be an enduring treatment for PD, it also behaves, as pioneering researcher Oleh
Hornykiewicz recognized early on, as “.far from perfect as a drug.”8 Levodopa’s limitations
at treating the full spectrum of parkinsonian signs and symptoms, as well as declining effective-
ness, have been recognized in follow-up of PD populations for 10 years and longer.9
How levodopa came to be developed as a therapy is instructive for the modern reader in that
it nicely illustrates a dictum of Louis Pasteur that “chance favors the prepared mind.” In fact,
several “prepared minds” lent rational and imaginative thinking to the understanding of the
distinctive pathology of the PD brain and how its biochemical changes might be reversed.
Highlighting these revolutionary events was the development of an animal model (reserpine-
induced akinesia), which was actually more of an analogy to parkinsonism than a rigorous
recapitulation of all clinical features. A key part of the research leading to levodopa as a therapy
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was emerging knowledge about how amino
acids could be transferred across the blood–brain
barrier (unlike dopamine, which, as a charged
molecule, is excluded). When Carlsson et al.10
first found levodopa could reverse the akinesia in
reserpinized rabbits, dopamine was regarded as
no more than an intermediate in the catechol-
amine synthesis pathway for norepinephrine and
epinephrine. Following that experiment, the
Swedish neuroscientist and Nobel Prize winner
Arvid Carlsson11 showed that dopamine was
present in the brain, was depleted with reserpine,
and could be restored with levodopa. Later, as
dopamine’s role in central nervous system
(CNS) neurotransmission became recognized,
levodopa achieved the status of “.the most nat-
ural substance.for treating.the striatal dopa-
mine deficiency syndrome.”8
Like the antituberculosis drug D-cycloserine,
another modified amino acid, levodopa lacks
the complexity of many drugs used in modern
medicine. The Swiss biochemist Marcus Gug-
genheim12 isolated levodopa from a natural
source, the broad bean (Vicia faba), and
characterized this compound in 1913. With
curiosity as to its biological roles, he heroically
self-administered a 2.5-g oral dose.12 This
promptly caused nausea and vomiting,12 side
effects that even today are sometimes experi-
enced by patients. In the 1940s, D,L-3,4-
dihydroxyphenylalanine as a racemic mixture
(levodopa is the proper name for just the levo
species) was administered to humans in experi-
ments that investigated its effects on blood
pressure13 and its metabolism to form dopa-
mine.14 Even though levodopa can be found in
trace amounts in the human brain and else-
where in the body, no other physiologic func-
tions have been determined for it. Levodopa
lacks a nucleic acid triplet codon and does not
find its way into protein formation.
Although this compound was recognized as
the starting source of catecholamine synthesis,
interest in levodopa as a potential therapy for
PD was nonexistent until after it was utilized
in the animal research experiments mentioned
above by Arvid Carlsson, who was investigating
reserpine’s sedative effect. Reserpine, a naturally
occurring alkaloid compound derived from the
snakeroot plant, was originally used in tradi-
tional medicine in India. Swiss chemists
extracted the active ingredient and developed
its therapeutic use in the 1950s as a powerful
antihypertensive agent.15 The attraction of
reserpine for Carlsson16 was its ability to
deplete brain stores of serotonin. His experi-
ments with reserpine searched for its effects
on other neurotransmitters as well. In collabo-
ration with Nils Åke Hillarp, Carlsson found
that reserpine depleted norepinephrine and epi-
nephrine in the adrenal glands of rabbits.17
Could this have relevance for neurotransmitters
in the brain? Carlsson endeavored to determine
if the tranquilizer effect of reserpine in mice and
rabbits was due to depletion of serotonin or the
catecholamines. In the first of a series of land-
mark experiments on the brain that explored
behavioral and neurochemical outcomes, he
studied mice and rabbits rendered immobile
by reserpine. Carlsson and colleagues discov-
ered that this motor impairment could not be
attributed to depleted serotonin.10,18 Adminis-
tering 5-hydroxytryptophan, the immediate
precursor of serotonin, had no effect on immo-
bility. Carlsson had used 5-hydroxytryptohan in
his experiments because he was aware that a
charged molecule like serotonin was unable to
cross the blood–brain barrier. Using similar
reasoning, he next tested racemic 3,4-
dihydroxyphenylalanine, which, as an amino
acid, could be transported across the blood–
brain barrier by means of a sodium-dependent
L-stereospecific uptake mechanism.19 In contrast
to the absence of effect conferred by the seroto-
nin precursor, D,L-3,4-dihydroxyphenylalanine
administration rapidly and almost completely
reversed the animal’s inability to move. This
profound (though transient) effect was enhanced
by pretreating the animals with iproniazid,
a monoamine oxidase inhibitor, supporting
“the assumption that the effect of 3,4-
dihydroxyphenylalanine was due to an amine
formed from it.”10 Carlsson developed a sensitive
fluorescent assay for dopamine, and his doctoral
students were able to demonstrate in the brains
of dogs that regional dopamine concentrations
were highest in the caudate and putamen (the
striatum).20 In this region, concentrations of
norepinephrine were only at trace levels.
The identity of dopamine as a major brain
neurotransmitter and integral to motor func-
tion (and subsequently to behavioral function)
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led to the analogy that depleted dopamine
concentrations might explain the pathophysi-
ology of PD, which in some respects resem-
bled the behavioral deficits of reserpinized
animals. At this point, there was no under-
standing of why this might be, especially since
norepinephrine concentrations did not rise
when levodopa was administered. It required
another breakthrough, recognition of the reg-
ulatory step in norepinephrine production
imposed by dopamine-b-hydroxylase in
norepinephrine-synthesizing neurons.21 Once
this discovery was made, the diversity of cate-
cholamine functions in the brain became bet-
ter understood as the era of dopaminergic
therapeutics opened for PD. Ironically, these
developments also ushered in a long period of
neglect for exploring norepinephrine as a ther-
apeutic target for PD.22
Offering a functional role to dopamine was
revolutionary at the time, especially since the
entire pathway of catecholamine synthesis
starting from phenylalanine and tyrosine had
yet to be worked out (though much earlier,
Hermann Blaschko23 identified the steps used
in creating epinephrine from levodopa). Recog-
nizing the role of dopamine and the simplicity
by which its function could be restored by levo-
dopa administration marked a turning point in
the eventual discoveries that led to harnessing
this drug for the treatment of PD. The variable
and inconclusive initial clinical results, how-
ever, led to this idea being largely unaccepted
by many neurologists.4,5 A number of scientific
questions remained unsettled. Many neuro-
scientists raised concerns that dopamine did
not meet established criteria for a neurotrans-
mitter and felt it was merely a precursor for
the other catecholamines. Furthermore, high
dosage of levodopa was suspected to be a pos-
sible neurotoxin (and responsible for killing
some of the animals in some experiments).24
Although tyrosine was suspected to be the
endogenous source for levodopa, the enzyme
responsible for this synthesis was not known.
The rate-limiting step, tyrosine hydroxylase,
was finally identified in 1964.25 It was largely
Carlsson’s work eventually convining neuro-
scientists that dopamine behaved as a neuro-
transmitter in brain, subserving many of the
motor activities mediated through the basal
ganglia (where the brain’s highest dopamine
concentrations were found).11,20
Next in the pathway for developing dopa-
minergic therapy of PD were the contribu-
tions of Austrian neuropharmacologist Oleh
Hornykiewicz.26 With an interest in measur-
ing and understanding the roles of dopamine
in the striatum, Hornykiewicz wondered
whether observations made in reserpinized an-
imals corresponded to findings in the PD
brain. He obtained autopsied brain specimens
from people who died of PD, postencephalitic
parkinsonism, or Huntington disease, and
without neurologic disease, and measured
dopamine and norepinephrine in a number
of brain regions. Ehringer and Hornykiewicz27
found a striking loss of dopamine in the par-
kinsonian brains, in contrast to Huntington
disease and control brain; the loss was partic-
ularly striking in the striatum, where the dopa-
mine content reduction was approximately
90%. Further research determined in the
upper brainstem that a small group of pig-
mented neurons, the substantia nigra, also
had major loss of dopamine.28 A functional
connection between the substantia nigra and
striatum was subsequently recognized by his-
tochemical imaging of axonal projections that
extend between these regions.29
The therapeutic dimensions of these discov-
eries soon became obvious to Hornykiewicz,
who collaborated with Austrian geriatrician
Walther Birkmayer to undertake clinical trials
with L-3,4-dihydroxyphenylalanine. This was
given IV in acute experiments to patients with
PD and those with parkinsonism due to von
Economo encephalitis. These clinical trials,
which were initiated in mid-1961, involved a
group of 20 patients who received levodopa at
doses between 50 and 150 mg.30 In some in-
stances, there were striking results, with marked
improvements in mobility for some of the pa-
tients who had long been bedridden or unable
to walk.26 The benefits became evident quickly
following the injections, and for some of the
patients, lasted for up to 24 hours. Unknown
to these investigators were similar experiments
that had been conducted 1 year earlier by a
research group in Japan led by Isamu Sano.
Their clinical experiment followed a similar
logic to the work of Carlsson, Hornykiewicz,
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and Birkmayer, in that they capitalized on their
own findings that dopamine concentrations in
the brain were greatest in several basal ganglia
regions.31 Since they also determined that stri-
atal dopamine concentration in an autopsied
PD brain was very much diminished, Sano32
went on to conduct a trial of racemic 3,4-
dihydroxyphenylalanine. In this study, the 5
patients who received 200 mg IV demonstrated
what the researchers described as minimal im-
provements of rigidity and tremor. The report
of the study did not receive attention outside of
Japan at the time and, presumably because of
the limited clinical benefits, this research group
did not pursue further experimentation.
Other research groups, aware of the findings
in reserpinized rodents, also attempted to
restore striatal dopamine concentrations and
relieve parkinsonian signs and symptoms using
the strategy of precursor therapy. In the 7 years
following the publication of Carlsson’s report,
and the work of Birkmayer and Hornykiewicz,
small-scale clinical investigations were carried
out in Germany, Italy, Canada, Sweden,
Finland, and the United States.33–47 For the
most part, these studies used IV administration
of either the levo or the racemic forms of 3,4-
dihydroxyphenylalanine and study designs that
were either open-label or placebo-controlled.24
Overall, the clinical results from these studies
were not impressive for achieving relief of par-
kinsonian features. During this period, consid-
erable basic neuroscience progress enhanced
knowledge about dopamine’s role in parkin-
sonism. However, the therapeutic approach of
administering a dopamine precursor seemed to
fail and there was considerable skepticism in the
early 1960s.
Birkmayer and Hornykiewicz, who made use
of the levo form of 3,4-dihydroxyphenylalanine
in their 1961 experiments, attempted to repli-
cate their findings in subsequent studies. They
reported on 200 patients with parkinsonian
symptoms who received 25-mg IV injections
of levodopa that were administered once or
twice weekly (together with an inhibitor of
monoamine oxidase).48 The results of this
approach were far less encouraging than what
they previously reported. They found evidence
for improvement in slowed movement for only
20% of the patients. While half of them showed
some reduction in clinical signs and symptoms
(such as impaired speech or posture), the re-
maining 30% were judged not to have experi-
enced any improvements.
The first to use high oral dosages of D,L-3,4-
dihydroxyphenylalanine in patients with PD
were the Canadian neuropharmacologist Pat-
rick McGeer and neurologist Ludmila Zeldo-
wicz in 1964.40 Starting with doses of 250 mg/
d, they built up the dose gradually by incre-
ments of 250 mg/d until a daily dosage of 5 g/
d was reached. They treated 10 patients (6 PD,
3 postencephalitic parkinsonism, and 1 arteri-
osclerotic) for several days, and 1 patient
received 3 g/d for 3 years. Two of the patients
showed some benefit. IV levodopa (250 mg)
was also given to 3 of the patients, of whom
only one of the 3 (a postencephalitic patient)
had a beneficial response. The authors con-
cluded that levodopa had little to offer as a
therapeutic agent in the treatment of
parkinsonism.40
The results of studies by both Birkmayer
and McGeer were particularly discouraging
and might have spelled the end of attempts
to treat PD with levodopa. Many experts,
including Melvin Yahr and Roger Duvoisin
in the late 1960s, were unimpressed with the
reported results using both D,L-3,4-
dihydroxyphenylalanine and levodopa.49,50
From today’s perspective, after decades of
experience in recognizing the diversity of par-
kinsonian signs and symptoms, disorders that
mimic PD, the impact of placebo effect on clin-
ical trials, the importance of controlled experi-
ments, and the need for testing long duration of
treatment, it seems no wonder that the small
doses of administered levodopa or racemic 3,4-
dihydroxyphenylalanine and the insufficient
trials of higher doses were doomed to fail.
Fortunately, another mindset as to the ther-
apeutic challenge in PD brought renewed
interest in levodopa. The American pharma-
cologist George Cotzias initiated a series of ex-
periments with treatment strategies that
differed from an approach to restore striatal
dopaminergic neurotransmission. Instead,
Cotzias51 envisioned that the treatment for
PD needed to target the absence of neuromel-
anin pigment in the substantia nigra. This
neuropathologic finding, which was also
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prominent in the parkinsonian and dystonic
disorder induced in Chilean miners from
chronic exposure to manganese, led Cotzias
and colleagues to treat a group of patients with
PD with intramuscular injections of
melanocyte-stimulating hormone and oral
administration of phenylalanine and 3,4-
dihydroxyphenylalanine (the latter 2 amino
acids in racemic forms). Although their treat-
ment hypothesis was not to replenish dopamine
in the brain, their trial with D,L-3,4-
dihydroxyphenylalanine showed dramatic effec-
tiveness, in contrast to melanocyte-stimulating
hormone and phenylalanine (each of which
exacerbated tremor).6 Among 16 patients receiv-
ing D,L-3,4-dihydroxyphenylalanine for treat-
ment periods ranging from 33 to 347 days, 8
patients showed either complete or marked
improvement of rigidity and tremor. The
doses used ranged from 3 to 16 g/d in divided
doses. An additional 2 patients showed some
improvements, and no patients worsened.
Among the adverse effects were nausea, vom-
iting, and postural lightheadedness. Cotzias
and colleagues6 observed that side effects
seem to be more prominent with rapid
increase of daily drug intake. They also found
that 25% of the patients developed a mild,
transient granulocytopenia in correlation to
intake of more than 200 g of the drug. The
salient points that differentiated this study
from previous clinical experience with levo-
dopa or D,L-3,4-dihydroxyphenylalanine are
the greatly increased daily intake that was
used and the sustained periods of treatment.
The slow buildup of dosage seems to be the
critical factor permitting an adequate test for
investigation of replacement therapy.6
The outcome of the initial 1967 clinical
study carried out by Cotzias et al.6 at
Brookhaven National Laboratories led to the
conclusion that further studies with levodopa,
instead of the racemic mixture, seemed “highly
warranted.” Two years later, Cotzias et al.7 re-
ported on a group of 28 parkinsonian patients
treated with levodopa. The patients were first
given placebo and then had levodopa intro-
duced in a regimen of substituting levodopa
for placebo gradually in dosing of 3 times per
day. Initially, they received 100 mg. Subse-
quent dosing, as tolerated, was increased by
200–300 mg every 2–4 days. The uptitration
was discontinued if optimized clinical benefit
was observed or if adverse effects developed.
The uppermost dosage was 8 g/d if needed.
The study was laborious, requiring several
months of in-hospital treatment and evalua-
tion. The results showed at least partial
improvement for most of the patients, and
10 of the 28 had “dramatic” improvement,
with another 10 classified as showing
“marked” improvement. The investigators
classified the remainder is having “moderate”
or “modest” improvement in parkinsonian
signs, and every feature of parkinsonism
showed some response, although not uni-
formly across all of the patients. To achieve
these effects, the average optimal dosage was
5.8 g per day (ranging from 4.2 to 7.5 g/d).7
With the high doses of levodopa used in
the study came adverse effects not previously
encountered. Nausea and vomiting were
common but could be prevented by the
development of pharmacologic tolerance with
the slow titration schedule. One of the pa-
tients showed psychic changes including
irritability, anger, hostility, paranoia, and
sleeplessness. Others showed improvements
in mental functioning that were described as
an effect of psychic “awakening” (the topic
of an influential book about high-dose levo-
dopa therapy of postencephalitic parkinson-
ism that was published in 1973 by Oliver
Sacks, Awakenings,52 followed by a Holly-
wood movie with the same title in 1990,
based on the book). As continued exposure
to levodopa was observed by Cotzias et al.,7
involuntary movements (dyskinesias) became
evident in half of them (and in some instances
took on relatively severe choreic or ballistic
features). During the course of their second
study, the L-aromatic amino acid decarboxyl-
ase inhibitor carbidopa was developed and
became available for some participants in
the clinical trial. This compound, blocking
peripheral conversion of levodopa to dopa-
mine, offered a synergistic action, permitting
lower doses of levodopa to be used. On this
basis, the optimized intake of levodopa
tended to be much lower.
The 1969 publication of clinical trial results
from the Brookhaven National Laboratories
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propelled levodopa into the forefront of PD
research, although these findings did not com-
pletely dispel the concerns of various experts.7
Additional clinical trials were needed to repli-
cate and confirm key information that arose
from the published studies. Since Cotzias’
notion that levodopa could restore neuromel-
anin seemed out of line with neuroscience
thinking of that time, further studies were
guided by increasing recognition that restoring
dopaminergic neurotransmission was likely
the basis for the benefits—as well is the
limitations—of levodopa therapy.
Next to undertake clinical research was
Yahr et al.50 at Columbia University, whose
study with levodopa was double-blind and
prospective. It included some patients who
crossed over between placebo and active treat-
ment. Comprising the clinical population
were 56 patients with presumed idiopathic
PD, 3 patients with postencephalitic parkin-
sonism, and 1 patient with probable progress-
ive supranuclear palsy. This study, published
in the same year as the second report by Cot-
zias et al.,7 administered levodopa 3–5 times
per day, starting with a daily intake of 750–
1,000 mg. The maximal dose was 8 g/d, and
in the study, the optimal effect for some pa-
tients was that dose or as low as 3 g/d.50 The
study results confirmed the dramatic improve-
ment of parkinsonism previously reported by
Cotzias et al.7 In the study by Yahr et al.,50
improvement was “marked” or “complete”
for two-thirds of the patients. Only 4 of the
patients were reported not to have any benefit.
The greatest response rate was for rigidity and,
to a lesser extent, for tremor and akinesia.
Nausea and vomiting were common side ef-
fects, especially during the first days of treat-
ment; these problems tended to be self-limited
and were less frequent among patients also
receiving anticholinergic drugs. Other adverse
effects included symptomatic postural hypo-
tension (affecting 14 of the patients) and
self-limited anorexia (affecting 19 patients).
Other problems included cardiac arrhythmias,
various psychic manifestations, and dose-
related dyskinesias (the latter affecting 37 of
the patients, most frequently occurring after
prolonged administration of relatively high
doses of levodopa). The impact of the study
was verification of levodopa as a remarkable
symptomatic treatment for disabling parkin-
sonism, but also emphasizing that this therapy
was not without limitations imposed by a vari-
ety of adverse effects.50
The results of the trial by Yahr et al.50
opened the support of the pharmaceutical
industry to make this compound available
(using a newly developed chemical chirally-
specific synthesis methodology that would
one day help to win a Nobel Prize). Linked
to the further development of levodopa was
the coadministration of carbidopa or another
inhibitor of peripheral L-aromatic amino acid
decarboxylase, benserazide. Each greatly
reduced many of the adverse effects and per-
mitted easier introduction of the drug by
clinicians.
Now almost a half-century after levodopa
proved its worth for symptomatic relief of par-
kinsonism, it might seem hard to believe that
the birth of such a useful therapy could be so
slow and challenging. The next decade, after
studies by Yahr et al.,50 brought optimal ther-
apeutics with levodopa into greater clarity. In
1970, levodopa achieved approval by the Food
and Drug Administration in the United States.
Its adoption as the major therapy for PD
became worldwide shortly thereafter. Despite
the development of drugs that mimic the ac-
tions of dopamine (dopaminergic agonists, of
which more than 2 dozen have undergone
clinical trials53), levodopa therapy remains
the most effective treatment for all stages of
PD.2 The medical literature pertaining to
levodopa therapeutics is extensive. The table
provides a listing of major reviews and sympo-
sia pertaining to levodopa therapeutics in the
first 2 decades following its initial develop-
ment.54–80
Overall, thousands of studies and other re-
ports have documented the benefits and limi-
tations of levodopa. It might seem that
modern neuroscience, by now, should have
developed a thorough understanding of how
levodopa works. The latter question might
seem curiously naive, since medical students
are regularly educated with the dogma that
this amino acid acts after it is decarboxylated
into dopamine, replenishing the deficient neu-
rotransmitter in the PD striatum. While there
S8 Neurology 86 (Suppl 1) April 5, 2016
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is no question about this mechanism, the
pharmacologic identity of levodopa, as
shown in recent research findings, is more
complex than this. Various clinical phenom-
ena such as the development of dyskinesias81
and the loss of the long-duration response82
are not readily explained by the simple con-
cept of levodopa as a dopamine precursor. A
large clinical trial (the ELLDOPA study)
raised questions as to the possibility that
levodopa might have disease-modifying
properties, though the study’s clinical and
neuroimaging endpoints were at odds with
each other.83
Basic neuroscience research into the mode
of action for levodopa has reported some
unique physiologic actions. Levodopa serves
as a Ca21-dependent “classic” neurotransmit-
ter in several brain regions.84 It also acts in the
CNS to downregulate L-aromatic amino acid
decarboxylase.85 Another intriguing finding has
been that levodopa is converted nonenzymati-
cally to several biologically active compounds.
One of these is 2,4,5-trihydroxyphenylalanine
(TOPA), which, like its quinone conjugate, is
an excitotoxin and can initiate various neuronal
responses in dopaminergic pathways unrelated
to stimulation of dopamine receptors (such as
activating neuronal firing, inward current flux,
and membrane depolarization).86 The actions
induced by TOPA and TOPA-quinone could
be blocked by administration of a glutamate
antagonist.87 The relevance of these and other
findings from studying levodopa pharmacology
in the rodent brain merit further exploration in
understanding clinical phenomena experienced
by the patient with PD.
Looking forward to a future of improved
levodopa therapy, many challenges need to
be overcome. Once patients lose the initial
long-duration response to this drug, its
peripheral pharmacokinetics govern clinical
responses.82 As a result, irregular absorption
and the drug’s rapid peripheral clearance
impose motor fluctuations, and patients can
experience considerable “off” time despite
regular dosing. Prolonged delay in uptake
of this medication as well as sensitivity to
dietary intake can add to the problems of
living with PD. Peak effect involuntary
movements and wearing-off dystonic phe-
nomena as well as nonmotor fluctuation ex-
periences are matters that patients (and their
clinicians) can struggle with after just a few
years of therapy.
Fortunately, the pharmaceutical industry
has risen to the challenge of creating alterna-
tive ways to deliver levodopa in order to
improve clinical responses. One example is
infusion of a microsuspension of carbidopa-
levodopa intestinal gel, introduced in Sweden
in the 1990s.88 The pharmacokinetic princi-
ples underlying the variability in levodopa’s
pharmacodynamics have become increasingly
understood in the past decade.89,90 Products
currently under development for more sus-
tained levodopa effect include gastric retentive
formulations,91–93 extended-release micro-
spheres controlling drug release,94 a levodopa
prodrug linked to nutritional molecules,95 a
Table Publications and monographs reviewing
clinical experience with levodopa for
Parkinson disease during the first 2
decades after its introduction
Barbeau and McDowell (1970)54
Birkmayer and Hornykiewicz (1970)55
Birkmayer and Riederer (1983)56
Boshes (1981)57
Brogden et al. (1971)58
Calne (1973)59
Hassler and Christ (1984)60
Lakke et al. (1977)61
LeWitt (1989)1
Markham et al. (1974)62
Marsden and Parkes (1977)63
McDowell and Markham (1971)64
McDowell and Barbeau (1974)65
O’Brien et al. (1971)66
Poirier et al. (1979)67
Presthus and Holmsen (1974)68
Rinne et al. (1980)69
Rose and Capildeo (1981)70
Sandler (1972)71
Schwarz and Fahn (1970)72
Shaw et al. (1980)73
Stern (1975)74
Sweet and McDowell (1975)75
Symposium (1971, 1972)76,77
Yahr (1973, 1974, 1975)78280
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formulation for inhalation uptake through the
lungs,96 and solubilized levodopa for continu-
ous subcutaneous infusion.97 Each of these
products is targeted against currently unmet
needs with levodopa and might become reali-
ties in the next few years. It seems unlikely that
levodopa will ever be replaced in the future,
only improved upon.
DEDICATION The authors dedicate this article to the
2 surviving pioneering researchers who made the
development of levodopa therapy possible: Arvid
Carlsson and Oleh Hornykiewicz.
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